Seattle Genomics Startup Variant Bio Secures Up to $50M Deal with Novo Nordisk to Study Metabolic Diseases Using Diverse Genomic Data
Seattle-based Variant Bio has partnered with Novo Nordisk in a multi-year deal worth up to $50 million to study metabolic diseases using genomic data from diverse populations. The collaboration aims to discover novel drug targets for diseases like obesity and diabetes by leveraging genetic data from globally diverse and underrepresented groups.
No comments yet.